Although infection with
Fasciola hepatica and
F. gigantica is found among cattle, sheep, goats, buffalo and some other ruminants such as horses and rabbits in most parts of the world, with rates as high as 90% were found among livestock in many countries (
1), human infection was found with low incidence in Africa, Asia and South America (
2).
Human fascioliasis has been increased during the last four decades and it has been estimated that 2,400,000 of human cases are found in 61 countries with 180 million inhabitants at risk (
3). For example, in Egypt, where 27.7 million people estimated to be at risk and the prevalence rate is between 7 and 17% in its rural areas, the infection becomes an emerging health problem (
4).
Reported in 1998 from 51 countries over 25 years, the total number of human cases was 7071. Of those, 3267 cases were from America, 2951 from Europe, 487 from Africa, 354 from Asia and 12 from Oceania. The increasing prevalence of human fascioliasis observed in parts of the world since 1980, has changed the status of the infection from secondary zoonotic disease to an important human parasitic disease and the infection is now considered as emerging or re-emerging infection (
5).
The total number of people infected with fascioliasis reported from different countries until 2002 were estimated to be 830,000 in Egypt, 742,000 in Peru, 360,000 in Bolivia, 20,000 in Ecuador, and 37,000 in Yemen. In some countries such as Bolivia, prevalence was reported to be as high as 70% (
6). In this country and in Peru, human and animal fascioliasis are considered to be hyperendemic (
7).
In Peru, the number of human fascioliasis has been increasing in the last decades and become an important parasitic disease (
8). In hyperendemic areas of Altiplano in Peru, located at a very high altitude of 3910 meters, the overall mean prevalence of
Fasciola hepatica was 24.3% with a range between 18.8 and 31.3%, with up to 2496 eggs per gram of feces (
9). Another place in which the outbreak of infection occurred was Eastern Anatolia in Turkey in 2008 (
10).
Studies undertaken in high endemic countries during recent epidemic have shown marked different epidemiological situations and transmission patterns in endemic areas (
11). High rate of human infection in epidemic forms were recently reported in some countries including Iran, where two epidemics of fascioliasis occurred between 1989-1999.
In Iran located in the Middle East, (
Figure 1), infection of cattle, sheep, buffalo and goats with
Fasciola hepatica and
F.gigantica were reported from many parts of the country (
12-
14). For examples in one study, it was shown that in parts of Gilan, where human epidemy occurred, 71.4% of cows were infected with
F. gigantica and 28.5% with
F. hepatica . The average rate of infection with
Fasciola among 445 cows in 3 areas of Gilan was 32.1% with rate as high as 55.2% (
15). High rate of animal infection was also reported from other parts of Mazandaran Province. Coprological studies showed that 25.4% of cattle and 7.3% of sheep were infected with fascioliasis (
16).
Map of Iran Showing the Location of Gilan Province With Location of Anzali District Shown in Green
Our studies in 2003 showed that in Mazandaran Province , 6.72% of cows, 1.98% of sheep, and 0.87% of goats were infected. From two buffalos examined, one was infected. The average number of worms recovered from each liver of sheep was: 4.6%
F. hepatica, 0.22 %
F. gigantica and 0.6%
Fasciola which their species could not be determined. The average numbers of each species found in liver of cows were, 1, 3.01 and 0.94, respectively (
17). These results may indicate the higher role of
F. gigantica in the transmission of fascioliasis among human (
18). Similar results were reported by Ashrafi et al. in 2004 (
19).
In addition to
F. hepatica and
F. gigantica, another species called
F. indica found infecting cattle in Iran (
14). Human infection with this species is reported from India and Korea (
20). Some believe that this species is the same as the hybrid of
F. hepatica and
F. gigantica reported above (
21).
Studies undertaken in some countries showed high financial losses due to infection of livestock with fascioliasis. For example in Switzerland, the financial losses due to bovine fascioliasis was estimated to be 52 million local currencies per annum which represents a median loss of 299 per infected animal. The losses arise from reduced milk yield and reduced fertility, meat production and the condemnation of livers (
22). The animal fascioliasis especially infected with
F. hepatica is a leading cause of production losses in cattle and sheep and other livestock , meat industries , reduced weight gain , milk production, and extinction. These economic losses due to infection of livestock with fascioliasis were well described in parts of Africa (
23). In Iran, the economic loss due to
Fasciola infection among livestock in a small slaughter house in Mazandaran found to be significant (
16).
Regarding human infection with fascioliasis in Iran, sporadic cases were reported from many parts of the country until 1988 when the first outbreak occurred in Gilan (
16,
24-
27).
Before 1988, up to 100 cases of human infection have been diagnosed per year in Iran, sporadic cases in epidemiologic studies or from ectopic parasite in various organs are mentioned in old literatures. Reports in 1969 indicate an outbreak of eosinophilia with unknown origin, which possibly was caused by fascioliasis in Gilan (
28). Presence of leptosporosis in Gilan which causes high eosinophilia should be considered in diagnosis of fascioliasis.
The first outbreak of fascioliasis, the largest in the world, occurred in Gilan in 1988. It began in February 1988. Total number of infected inhabitants estimated to be between 9008 and 20,000, but more accurate number might be 10,000, which is calculated based on the total population of infested city of Port of Anzali on the Caspian Sea which was 100,000. Although infection was found in all age groups, the highest rate was found in age groups below 35 years old. The peak of transmission was from February to June. In this outbreak, cases were diagnosed parasitologically and serologically in Gilan and Mazandaran, where 6 million inhabitants were considered at risk. Serological examination of 452 inhabitants of Anzali using ELISA method in 1988 showed infection rate of 50%. The rate was 34.95 as immunoelectrophoresis was used. Higher infection rates were found in Port of Anzali and the town of Taleghani. Among positive cases, 13.7% showed IgG, 26.5% had IgG and IgM and 37.6% showed IgM (
29).
In one study, examination of 225 inhabitants in 9 districts of the Port of Anzali revealed a rate of 20% fascioliasis (
26) and in another study, 45 were found infected from 458 persons examined (
27). In Gilan, blood eosinophilia of 37.4% was found from 884 inhabitants, of whom 423 had
Fasciola eggs in their stool (
30). The outbreak lasted for 18 months, but examination of 2200 inhabitants from 44 villages in Lahijan did not show any infected cases after two years (
31).
The number of infected cases found between 1984 and 1996 in Gilan was 1100, of whom 904 were in the Port of Anzali, 94 cases in Lahijan, 57 cases in Rasht, 9 case in Astaneh, 8 cases in Langroud, 5 cases in Soume`eh Sara and one case in Roudsar (
32).
Serological tests undertaken by Assmar et al. on 452 inhabitants of 8 regions of Anzali Port for
Fasciola antibody, using ELISA one year after the first outbreak of Gilan, showed that infection in females was higher than males and the highest rate was among age groups of below 20 years old. The highest rate was in the town of Taleghani (
29).
In another study undertaken a year after the outbreak in Gilan, clinical examinations were undertaken for 2364 inhabitants of the infested areas: stool examination of 884 among this group revealed the presence of eggs of Fasciola among 36% of them.
Among patients with eosinophilia of 30% or more, 75% had passed
Fasciola eggs in their stool. Seventy percent of positive cases were female and the highest prevalence was found among age group of 20 to 30 years old. The manifestations observed in patients were weight loss, epigastric pain, perspiration, mussel ache, fever, anorexia, coughing and hepatosplenomegaly (
33).
Second outbreak occurred in 1999 among the population of the ports of Anzali in the Caspian Sea. The number of infected cases in this epidemy was estimated to be 2465.
In Mazandaran, all 107 human cases were diagnosed between the 1999 and 2002. No differences were found regarding the infection rates among various genders and age groups. Lower human and animal infections were found in the eastern Mazandaran (
16).
The number of infected cases reported from health centers in parts of Gilan from 1998 to 2004 is shown in
Table 1. As it is shown in this table, the highest number of cases was reported in 1999 and the cases were found among inhabitants until 2004. Most of cases were from Anzali Port (
34).
| Reported From | No. Per Year |
|---|
| 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 |
|---|
| Anzali City Health Center | 211 | 2465 | 1161 | 348 | 445 | 143 | 331 |
| Rasht City Health Center | _ | 691 | 114 | 95 | 91 | 32 | _ |
| Other Health Centers | _ | _ | _ | 59 | 47 | 3 | _ |
In addition to two above mentioned outbreaks in north of Iran, 17 cases of human fascioliasis were found in a district of Kermanshah in 2000. The youngest patient was four years old and the oldest was 49 years old. 53% of the patients were female and the rest were male. All patients were farmers and 82% of them had a history of watercress ingestion in a period of 1 to 2 months before the admission. The highest number of cases was found during the spring of 2001 (
35).
While the use of Praziquantel for the treatment of cases in infested areas showed no effect, Bithionol usage showed a cure rate of 69% among patients (
36). Further treatment efforts using Triclabendazole showed this drug to be more effective than Bithionol (
37). Oral administration of 10 mg/kg of Triclabendazole for 1-3 days in fascioliasis infested areas of Iran resulted in high cure rate among infected cases (
38).
In another study, patients from Gilan who were treated with Triclabendazole but remained positive by stool examination and serologically were treated with a dosage of 1.5 g/d of Metronidazole orally for three weeks. Evaluation of cure rates undertaken 3 and 12 months after the end of therapy showed that all were negative observing serology and egg in stool examination (
39).